US20040039054A1

US20040039054A1 - Use of L-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs

Info

Publication number: US20040039054A1
Application number: US10/462,682
Authority: US
Inventors: Sonia Moretti
Original assignee: Sigma Tau Industrie Farmaceutiche Riunite SpA
Current assignee: Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date: 1995-08-03
Filing date: 2003-06-17
Publication date: 2004-02-26
Also published as: ITRM950544A0; AU719906B2; KR100412532B1; ES2216050T3; DE69631768D1; ATE260654T1; AR004503A1; HK1015273A1; WO1997005864A2; DE69631768T2; AU6469096A; KR19990036149A; ITRM950544A1; EP0839033A2; CA2228266C; RU2269340C2; CN1193912A; IT1277897B1; BR9609947A; CA2228266A1

Abstract

The present invention provides a novel use of L-carnitine, the derivatives thereof and their pharmacologically acceptable salts in combination with antiretroviral drugs for reducing ceramide levels and enhance the activity of the aforesaid antiretroviral drugs for the therapeutic treatment of HIV-infection and AIDS.

Description

The present invention relates to a novel therapeutic use of L-carnitine, the derivatives thereof and their pharmacologically acceptable salts in combination with antiretroviral drugs for the therapeutic treatment of HIV-infection and AIDS. More particularly, the present invention relates to the use of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms, and the pharmacologically acceptable salts thereof in combination with nudeoside-like inhibitors of reverse transcriptase, non-nucleoside inhibitors of reverse transcriptase and inhibitors of HIV protease, for reducing ceramide levels and enhance the activity of the aforesaid antiretroviral drugs in HIV-infected patients.

Most of the pathogenetic mechanisms that contribute to the progression of infection due to human immunodeficiency virus 1 or 2 (HIV-1, HIV-2) are directly or indirectly related to the state of general activation of the immune system.

Chronic activation of the immune system potentiates viral replication both via secretion of a number of cytokines favouring HIV expression and by maintaining a reserve of activated immune cells which act as targets for the HIV and facilitate its replication.

Moreover, the state of persistent activation of the immune system induces abnormalities of such a nature (e.g. an increased apoptosis) as to lead to a progressive weakening of the immune responses.

A vicious circle is thus set up: progressive loss of competence of the immune system→viral dissemination→reduced elimination of the virus→chronic activation of the immune system. The above process may last for years until such a marked deterioration of the immune system occurs as to lead to an uncontrolled viral replication and to the onset of opportunist infections, or to the development of acquired immuno-deficiency syndrome (AIDS).

On the basis of the pathogenetic mechanisms outlined above, it appears clear that any anti-HIV treatment must be aimed at reducing viral replication and at blocking the deterioration of the immune system.

As regards antiretroviral therapy, unfortunately HIV is characterized by a high degree of genetic variability originating above all in the very substantial lack of precision of reverse transcriptase. The retroviral enzyme lacks enzymatic systems for the control of possible transcription errors. The result is the emergence of variants of the virus—over a range which is a function of viral replication—which are responsible for the progressive eluding of the immune system and of resistance to antiretroviral drugs. In the case of zidovudine (AZT, ZDV) the loss of clinical efficacy in situations of monotherapy is an extensively acknowledged fact. Even the anti-retroviral agents discovered more recently, e.g. zalcitabine [ddc], didanosine [ddI] and lamivudine [3TC] suffer from the same drawback.

It has recently been demonstrated that ceramide stimulates HIV expression. What is more, ceramide is one of the factors capable of inducing cellular apoptosis, a phenomenon which is increased in subjects with HIV infection and which contributes to the depletion of TCD4 and TCD8 lymphocytes. It thus appears evident that changes in the concentration or metabolism of ceramide may affect the viral load and cellular apoptosis in HIV-infected subjects (Papp B. et al., AIDS, Res. Hum. Retrovirus, 10(7), 775-80).

Surprisingly, it has now been found that L-carnitine and derivatives thereof, i.e. the acyl L-carnitines wherein the acyl group, straight or branched has 2-6 carbon atoms and the pharmacologically acceptable salts thereof inhibit ceramide synthesis by at least 25% and when they are used in combination with antiretroviral drugs such as e.g. AZT, stavudine [d4T], fluorothymidine [FLT], azidouridine [Azdu], phosphonated acyclic nucleosides [PMEA], HIV-1 specific nucleosides ([TSAO], zalcitabine [ddC], didanosine [ddI] and lamivudine [3TC], dipyrido-diazepinones, tetrahydroimidazobenzodiazepinones, pyridones or L drugs, bis-heteroarylpiperazines, derivatives of alpha-anilinophenyl-acetamide, derivatives of quinaxoline, Ro-31-8959, U-81749, KNI-227, SC-52151, HOE/BAY 793 and the like, enhance the antiretroviral activity and defense of the immune system exerted by these drugs.

Pharmaceutically acceptable salts of L-carnitine or acyl L-carnitine include, in addition to the inner salts, any salt of these with acids which do not give rise to undesirable toxic or collateral effects. These acids are well known to the average skilled pharmacologists and experts in pharmaceutical technology.

Non-limiting examples of suitable salts include the chloride; bromide; iodide; aspartate, particularly acid aspartate; citrate, particularly acid citrate; tartrate; phosphate, particularly acid phosphate; fumarate, particularly acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, particularly acid maleate; orotate; oxalate, particularly acid oxalate; sulphate, particularly acid sulphate; tricholoroacetate; trifluoroacetate and methanesulphonate.

Particularly preferred are L-carnitine, acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine.

The combined administration of L-carnitine and its derivatives as defined above plus an antiretroviral agent is generally conducted via the oral or parenteral routes at daily doses ranging from 1 to 500 mg/kg, with a particular preference for doses from 20 to 100 mg/kg, in a ratio of L-carnitine and its derivatives as defined above to the antiretroviral agent ranging from 1:40 to 40:1, with a particular preference for ratios from 1:10 to 10:1.

Conveniently, the administration will take the form of a unit dose including both active ingredients and this may also include excipients and additional active ingredients well-known to those skilled in this art, such as, for instance, dextran, TNF-alpha inhibitors (e.g. pentoxyphylline), glutathione and other antioxidant drugs (e.g. acetylcysteine), immuno-modulatory drugs, immunosuppressive or chemotherapeutic agents, vitamins and oligoelements.

Lastly, it should be noted that everything suggests that other basic amino acids, particularly lysine, basic amino acid acyl derivatives and their pharmaceutically acceptable salts are capable of reducing the levels of ceramide and of potentiating the activity of antiretroviral drugs for the therapeutic management of HIV infection and AIDS.

The purpose of the examples that follow here below is to illustrate the invention and they should not be construed as in any way limiting the range of possibilities.

EXAMPLE 1

The effect of administration of a combination of L-carnitine (8 g daily by mouth for 4 weeks) plus AZT (600 mg daily by mouth) on 13 patients suffering from AIDS with normal serum and intracellular levels of carnitine and acetylcarnitine, who had previously been submitted to treatment with AZT (600 mg daily by mouth) for at least 6 months, was evaluated. [0017]
The determinations were carried out prior to the combined treatment, while patients were taking only AZT (T0), after 4 weeks of therapy with the L-carnitine-AZT combination (T1) and one month after discontinuation of treatment with L-carnitine (T2), leaving the patients on AZT alone. TCD4 lymphocytes were measured by flow cytometry by means of a specific monoclonal antibody (number of lymphocytes per mm[0018] ³) and the apoptotic lymphocytes by flow cytometry after staining with propydium iodide, quantifying the cells with hypodiploid nuclei (number of lymphocytes per 50,000 cells). The viral load (number of viral particles per ml of serum) was determined by quantifying HVI-1 RNA by means of a polymerase chain reaction (Amplicor HIV detection system by Roche). The Wilcoxon test was used for the statistical processing.

The results are shown in Table 1 here below.

TABLE 1


			HIV
	TCD4	Apoptotic lymphocytes/	(viral particles
Pat-	lymphocytes/mm³	50,000 ceUs	per ml)

ient	T0	T1	T2	T0	T1	T2	T0	T1

1	195	211	172	85	59	130	3.500	900
2	239	254	264	112	37	84	2.400	1.600
3	172	176	176	90	29	35	2.800	1.600
4	254	287	279	91	40	39	1.700	1.500
5	141	165	165	59	47	66	62.000	1.100
6	125	205	146	280	81	36	2.200	2.000
7	40	51	47	41	26	88	3.800	3.100
8	309	423	411	82	67	41	5.900	3.900
9	303	502	402	102	20	41	5.300	3.300
10	47	46	43	65	42	64	2.300	2.300
11	120	120	116	52	52	55	1.400	1.400
12	52	60	41	148	111	104	900	1.300
13	26	378	378	113	38	54	43.000	7.000
Mean	178	221	203	101	50	64	10.553	2.384
S.D.	101	144	133	61	25	64	19,070	1.661
Sta-		0.001	0.02		0.001	0.04		0.004
tis-
tical
sig-
nifi-
cance

In the same subjects the levels of lymphocyte ceramide, measured by means of DAG (diacylglycerol) kinase assay (Cifone M. G. et al., J. Exp. Med. 180(4), 1547-52) dropped from 48±8 pmol/10[0020] ⁶lymphocytes measured prior to combination treatment (T0) to 27±5 pmol/10⁶lymphocytes (T1) (P<0.01), rising again to 38±9 pmol/10⁶lymphocytes one month after discontinuation of L-carnitine (T2).
These results clearly show that treatment with AZT alone, even when prolonged previously for more than 6 months (T0), does not afford those immunological and virological improvements that are achievable with the L-carnitine-AZT combination in only 4 weeks (T1). These improvements tend to decline on discontinuing treatment (T2). [0021]

EXAMPLE 2

Four subjects with AIDS were treated with 600 mg of AZT daily by mouth. Of these, two were also treated with L-carnitine 3 g daily. The total duration of the treatment was 6 months. Muscle biopsies were performed before and after treatment. The ceramide present at muscle cell level was determined before and after treatment, after sonicating and homogenizing the biopsy material. The viral load was determined in the same muscle homogenates, as described in Example 1. [0022]

The results are shown in Table 2 here below.

TABLE 2


Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
ceramide	ceramide	HIV (viral	HIV (viral
(pmoL/mg	(pmol/mg	particles/mg	particles/mg
protein)	protein)	protein)	protein)

Patient 1	89	95	3,800	4,100
(AZT)
Patient 2	95	103	5,900	5,800
(AZT)
Mean	92	99	4,850	4,950
S.D.	4	6	1,485	1,202
Statistical		n.s.		n.s.
significance
Patient 3	129	39	10,200	3,200
(AZT + L-carnitine)
Patient 4	79	27	5,100	1,300
(AZT + L-carnitine)
Mean	104	33	7,650	4,950
S.D.	35	8	3,606	1,344
Statistical		0.01		0.05
significance

It is apparent that treatment with the L-carnitine-AZT combination is distinctly more effective in reducing the viral load and levels of ceramide, also at muscle level, compared to treatment with AZT alone. [0024]

Claims

1. Use of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and their pharmacologically acceptable salts for producing a medicament suitable for reducing ceramide levels for the therapeutic treatment of HIV-infection and AIDS.

2. The use of claim 1 in combination with nucleoside-like inhibitors of reverse transcriptase, non-nucleoside inhibitors of reverse transcriptase and inhibitors of HIV protease, for producing a medicament suitable for reducing ceramide levels and enhancing the activity of the aforesaid antiretroviral drugs for the therapeutic treatment of HIV-infection and AIDS.

3. The use of claim 1 or 2, wherein L-carnitine is used.

4. The use of claim 1 or 2, wherein the acyl carnitine is isovaleryl L-carnitine.

5. The use of claim 1 or 2, wherein a basic aminoacid, an acylated basic aminoacid or a pharmacologically acceptable salt thereof is used.

6. An orally or parenterally administrable pharmaceutical composition for reducing ceramide levels for the therapeutic treatment of HIV-infection and AIDS which comprises as active ingredient an amount of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof, effective for reducing ceramide levels, and at least one pharmacologically acceptable excipient.

7. An orally or parenterally administrable pharmaceutical composition for the therapeutic treatment of HIV infection and AIDS in combination with the administration of nucleoside-like inhibitors of reverse transcriptase, non-nucleoside inhibitors of reverse transcriptase or HIV-protease inhibitors, which comprises an amount of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof, effective for reducing ceramide levels and viral load and for enhancing the immunocompetence of HIV-infected patients, and at least a pharmacologically acceptable excipient.

8. An orally or parenterally administrable pharmaceutical composition in unit dosage form for reducing ceramide levels and enhancing the efficacy of antiretroviral drugs for the therapeutic treatment of HIV-infection and AIDS, which comprises at least one antiretroviral drug selected from nucleoside-like inhibitors of reverse transcriptase, non-nucleoside inhibitors of reverse transcriptase or HIV-protease inhibitors and an amount of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof, effective for reducing ceramide levels and viral load and enhancing the immunocompetence of HIV-infected subjects, and at least a pharmacologically acceptable excipient.

9. The pharmaceutical composition of claim 6 or 7 wherein the amount of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof is such that the daily dose of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof and antiretroviral drug is from 1 to 500 mg/kg and the ratio between L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and their pharmacologically acceptable salts thereof and the antiretroviral drug is from 1:40 to 40:1.

10. The pharmaceutical composition of claim 6 or 7 wherein the amount of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and their pharmacologically acceptable salts thereof is such that the daily dose of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof and antiretroviral drug is from 20 to 100 mg/kg and the ratio between L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof and the antiretroviral drug is from 1:10 to 10:1.

11. The orally or parenterally administrable pharmaceutical composition of claim 8, in unit dosage form, wherein the amount of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof is such that the daily amount of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof and antiretroviral drug is from 1 to 500 mg/kg and the ratio between L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof and the antiretroviral drug is from 1:40 to 40:1.

12. The orally or parenterally administrable pharmaceutical composition of claim 8 in unit dosage form, wherein the amount of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof is such that the daily dose of L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof and antiretroviral drug is from 20 to 100 mg/kg and the ratio between L-carnitine, acyl L-carnitines wherein the acyl group, straight or branched, has 2-6 carbon atoms and the pharmacologically acceptable salts thereof and the antiretroviral drug is from 1:10 to 10:1.

13. The composition of any of the claims 1-12 which further comprises at least one component selected from dextran, alpha-TNF inhibitors, antioxidant drugs, immunomodulators, immunosuppressants, chemotherapeutic agents, vitamins and oligoelements.